AuntMinnie

MAY 1, 2023

Blue Earth Diagnostics is highlighting results from a clinical study that ha. prostate radiopharmaceutical licensing Blue Earth to highlight PET study results at ASTRO Blue Earth wins FDA nod for PSMA-PET tracer NDA

Clinic 52

Clinic Radiopharmaceuticals Diagnostic 52

Imaging Technology

SEPTEMBER 8, 2023

milla1cf Fri, 09/08/2023 - 16:25 September 8, 2023 — Positron Corporation , a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA. on September 18, 2023.

Clinic 95

Clinic Radiopharmaceuticals Medical Device IT 95

Imaging Technology

JULY 5, 2024

68Ga-DOTA-RM2 will be used as a companion diagnostic. While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate,” said Brian Markison, Lantheus CEO.

Diagnostic 52

Diagnostic Radiopharmaceuticals Disease IT 52

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 75

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 75

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Chief Executive Officer of Blue Earth Diagnostics. from October 1 to 4, 2023. Gauden , D.Phil., Kuo, MD, Ph.D.,

Diagnostic 93

Diagnostic Radiation Oncology Radiation Clinic 93

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc. The post Martin B.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

TTG Imaging Solutions

AUGUST 1, 2023

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc. The post Martin B.

Nuclear Medicine 40

Nuclear Medicine Clinic Radiopharmaceuticals Diagnostic Imaging 40

Imaging Technology

JUNE 21, 2023

POSLUMA is now commercially available through multiple radiopharmacies of PETNET Solutions, the primary manufacturer and commercial distributor for Blue Earth Diagnostics in the United States. Chief Executive Officer of Blue Earth Diagnostics Ltd. Blue Earth Diagnostics is at Booth 6025 and PETNET Solutions is at Booth 6075.

Diagnostic 75

Diagnostic Radiopharmaceuticals Imaging Medicare 75

AuntMinnie

APRIL 4, 2024

Life Molecular Imaging (LMI) and Sofie Biosciences have begun offering the Neuraceq ( florbetaben F-18) PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio. With this expansion, LMI continues driving commercial sales of Neuraceq around the U.S.

Radiopharmaceuticals 85

Radiopharmaceuticals Imaging Disease Diagnostic 85

AuntMinnie

JANUARY 3, 2024

NorthStar Medical Radioisotopes and Chester Springs, PA-based Curadh MTR have entered a strategic collaboration agreement to develop radiopharmaceuticals for the treatment of primary and metastatic solid tumors.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Clinic Medical 52

AuntMinnie

DECEMBER 14, 2023

ITM Isotope Technologies Munich has signed a licensing agreement with the life science business of Merck KGaA in Darmstadt, Germany, for the clinical development and commercialization of radiolabeled folate derivatives. The company plans to advance this to phase I clinical testing.

Radiopharmaceuticals 52

Radiopharmaceuticals Clinic Diagnostic Medical 52

AuntMinnie

JUNE 27, 2023

Blue Earth Diagnostics, a Bracco company, is highlighting results from a stud. Read more on AuntMinnie.com Related Reading: FDA approves new PET tracer for prostate cancer imaging Blue Earth touts clinical results PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Clinic Imaging 52

AuntMinnie

MAY 30, 2023

Food and Drug Administration (FDA) has approved Blue Earth Diagnostics. Read more on AuntMinnie.com Related Reading: Blue Earth touts clinical results Blue Earth highlights results from PET tracer trial PET tracer shows promise in imaging of brain tumors Blue Earth touts PSMA radiotracer study Blue Earth moves toward U.K.

Radiopharmaceuticals 52

Radiopharmaceuticals Imaging Diagnostic Clinic 52

AuntMinnie

JUNE 20, 2024

MIBI-SPECT/CT is considered the standard technique for guiding these surgeries, yet several phase II clinical trials suggest advantages of a newer approach using FCH-PET, such as superior spatial resolution for detecting small adenomas and lower radiation exposure to patients, they noted. The full study is available here.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Imaging Clinic 105

Imaging Technology

OCTOBER 11, 2023

-based company, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). SOFIE will continue its clinical development and commercialization program with [18F]FAPI-74 in the U.S. Financial terms were not disclosed. Sherly Mosessian , Ph.D,

Healthcare 93

Healthcare Healthcare Pharmaceutical Radiopharmaceuticals 93

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

FEBRUARY 12, 2024

In patients treated at a memory clinic at Huashan Hospital in Shanghai, amyloid PET scans detected brain pathology associated with the disease and led to changes in treatment plans in 36.5% The clinical utility of amyloid PET scans has been systematically studied in many other countries. The full study is available here.

PET Scan 99

PET Scan Disease Diagnose Radiopharmaceuticals 99

Imaging Technology

MAY 14, 2024

milla1cf Tue, 05/14/2024 - 12:45 May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on their 40-year history of clinical and research collaboration. This alliance will help UH expand patient access and transform cancer care from discovery to recovery.

Hospital 103

Hospital Magnetic Resonance Imaging Radiopharmaceuticals Disease 103

Imaging Technology

JANUARY 23, 2024

We see a growing interest for these high energy machines, driven by an increasing number of clinical trials exploring new diagnostic or radiotherapeutic molecules.” To date, six Cyclone® 70 MeV machines and over 35 cyclotrons of 30 MeV have been installed worldwide.

Radiopharmaceuticals 96

Radiopharmaceuticals Disease Diagnostic Clinic 96

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

AuntMinnie

JUNE 14, 2024

Ben Greenspan, MD, of VA Augusta (GA) Health, said he has never seen a patient harmed by a diagnostic extravasation or infiltration, and the claim that thousands of patients are being injured is "just not right. That might do away with diagnostic concerns, Flannery noted.

Nuclear Medicine 52

Nuclear Medicine Radiation Radiopharmaceuticals Medical 52

TTG Imaging Solutions

FEBRUARY 17, 2022

Be sure to visit us at booth #304 Monday, February 21 and Tuesday, February 22 to discover solutions for equipment, nationwide service, parts, and clinical support. We aim to maximize customer satisfaction through a relentless pursuit of quality, a broad portfolio of services, and commitment to continuous improvement.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Diagnostic Imaging 52

Imaging Technology

JUNE 20, 2024

More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging. In the hands of clinicians, these tools help make the practice of precision care more accessible and aim to help improve patient outcomes globally.”

Healthcare 80

Healthcare Healthcare Nuclear Medicine Computed Tomography 80

TTG Imaging Solutions

MAY 5, 2023

operates a diagnostic imaging turnkey business and serves as an OEM and service provider for a well-respected portfolio of fixed and mobile solid-state nuclear medicine cameras. Through a nationwide network of field service engineers, TTG offers equipment, maintenance and repair services, clinical staffing, and radiopharmaceutical products.

Imaging 52

Imaging Radiopharmaceuticals Radiation Oncology Nuclear Medicine 52

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Chief Executive Officer of Blue Earth Diagnostics. Blue Earth Diagnostics received U.S. Gauden, D.Phil.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

Imaging Technology

NOVEMBER 2, 2023

2] In addition to the potential benefits of these AI models in clinical use, with roughly 5,000 immunotherapies in development today [3] , selecting patients more likely to respond could also help drug developers to speed up and increase the likelihood of success of clinical trials.

Pharmaceutical 59

Pharmaceutical Healthcare Healthcare Clinic 59

Imaging Technology

APRIL 2, 2024

announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. This includes continuing to grow MIM Software’s offerings for end-to-end standardization across large healthcare system fleets.

Healthcare 95

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 95

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. They're also mindful of the multiple dedicated teams required to build a theranostics clinic properly. However, few freestanding theranostics centers exist today.

Nuclear Medicine 86

Nuclear Medicine Radiation Oncology Nursing Radiation 86

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. Our ongoing Phase 1/2 clinical trial ( NCT05413850 ) is evaluating 177Lu-rhPSMA-10.1

Radiopharmaceuticals 92

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 92

Open Medscience

MAY 14, 2024

Positron Emission Tomography Imaging has advanced with cutting-edge technologies, enhancing diagnostic accuracy and expanding clinical applications dramatically. The post Breakthroughs in Positron Emission Tomography Imaging appeared first on Open MedScience.

Imaging 52

Imaging Diagnostic Clinic Nuclear Medicine 52

AuntMinnie

JANUARY 30, 2024

Efforts to bring quantitative MRI analysis into clinical practice received a boost with the availability of two new Category III Current Procedural Terminology (CPT) codes for brain MRI. As such, radiopharmaceuticals consisting of a TSPO ligand coupled to a PET radioisotope serve as effective imaging agents for neuroinflammation.

MRI 100

MRI Radiopharmaceuticals Disease Imaging 100

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 89

Radiopharmaceuticals Imaging Pharmaceutical Disease 89

AuntMinnie

JUNE 3, 2024

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals Radiation Radiation Oncology 105

Imaging Technology

JULY 11, 2023

We are delighted by our collaboration with Ratio Therapeutics in advancing the clinical development of RTX-1363S as a FAP-targeted diagnostic to the clinic," stated Etienne Montagut, Lantheus' Chief Business Officer. "By RTX-1363S has the potential to transform the way we detect and monitor various epithelial-derived cancers."

Radiopharmaceuticals 70

Radiopharmaceuticals Imaging Pharmaceutical Disease 70

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 82

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 82

TTG Imaging Solutions

NOVEMBER 1, 2021

The organization brought a robust customer base in the mid-west along with a strong group of field service engineers The following executive leadership changes are effective November 1, 2021: Jack Tomayko, Ph.D., Remaining in their current roles are John Nalley, EVP of Equipment Service Operations, and Hunter Forestier, VP of Sales and Marketing.

Nuclear Medicine 52

Nuclear Medicine Imaging Radiopharmaceuticals Medical Imaging 52

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.

Diagnostic 92

Diagnostic Radiopharmaceuticals Imaging Radiation 92